Key terms

About AMRX

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest AMRX news

Apr 08 5:00pm ET Bausch Health (NYSE:BHC) Falls 7% amid New Legal Issues Apr 08 2:57pm ET Bausch suit creates added uncertainty on B+L spin, says TD Cowen Apr 05 6:19pm ET Bausch Health files patent lawsuit against Amneal Pharmaceuticals Mar 25 4:06pm ET Amneal receives FDA approval for ciprofloxacin, dexamethasone otic suspension Mar 21 7:17am ET Amneal Pharmaceuticals price target raised to $8 from $6 at Piper Sandler Mar 16 2:01am ET Amneal Pharma and the AI Dilemma: Balancing Innovation with Emerging Risks and Regulations Mar 08 4:16pm ET Amneal Pharmaceuticals (NASDAQ:AMRX) Presents a Compelling Option for Value Investors Mar 07 7:20am ET Amneal Pharmaceuticals management to meet with Piper Sandler Mar 01 5:25pm ET Strong Growth Ahead: Buy Rating for Amneal Pharmaceuticals Amidst Promising Product Launches and Financial Performance Mar 01 7:05am ET Options Volatility and Implied Earnings Moves Today, March 01, 2024 Mar 01 6:22am ET Amneal Pharmaceuticals Announces Upcoming Results Webcast Mar 01 6:07am ET Amneal Pharmaceuticals sees FY24 adjusted EPS 53c-63c, consensus 60c Mar 01 6:06am ET Amneal Pharmaceuticals reports Q4 adjusted EPS 14c, consensus 9c Feb 27 8:12am ET Amneal in licensing agreement with Zambon Biotech for IPX203 Feb 22 5:09am ET Barclays Remains a Buy on Amneal Pharmaceuticals (AMRX) Feb 08 4:36pm ET Amneal provides complete response resubmission to FDA for IPX203 NDA Jan 29 5:07am ET Barclays Sticks to Their Buy Rating for Amneal Pharmaceuticals (AMRX) Jan 25 7:36am ET Knight Therapeutics, Amneal Pharmaceuticals enter license agreement

No recent press releases are available for AMRX

AMRX Financials

1-year income & revenue

Key terms

AMRX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

AMRX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms